Stay updated with breaking news from Adicet Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Announced interim safety and efficacy data for ADI-001 in ongoing Phase 1 study for the potential treatment of relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL); Next data update expected in Q2 2023Announced preclinical data for differentiated chimeric antigen receptor (CAR) and chimeric adaptor (CAd) progr...
Dublin, Jan. 06, 2023 (GLOBE NEWSWIRE) -- The "Global Cellular Immunotherapy Market Size, Share & Trends Analysis Report by Therapy Type (CAR T Cell...
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on December 30,...
/PRNewswire/ -- The "CAR-T Cell Therapy Market by Target Indications, Target Antigens, Key Players and Key Geographies - Global Forecast 2022-2035" report has...
ADI-001 demonstrated 75% overall response rate (ORR) and 69% complete response (CR) across all dose levels with favorable safety and tolerability profile in patients with relapsed/refractory high-grade aggressive NHL, as of December 5, 2022 data-cut date 100% ORR and CR rate in 5/5 anti-CD19 autologous chimeric antigen receptor T cells (CAR-T) relapsed large B-cell lymphoma (LBCL) patients 86% CR rate in LBCL patients across dose level three (DL3) and above (75% CR rate in LBCL patients across all dose levels) Both dose level 2 (DL2) and DL3 demonstrated a six-month CR rate of 33%; Patient fol...